The Apex Times
Above the Noise
Business Wire
BusinessLeonardo DRS wins $63 million production order for Family of Weapon Sights, reinforcing dismounted sensing pushThe Apex TimesBusinessGoldman Sachs tops Street expectations in equity trading, while fixed income and rates lagThe Apex TimesBusinessPatient Capital Management points to Meta’s long-term upside in its 2026 investor letterThe Apex TimesBusinessTesla touts brisk vehicle deliveries, while investors weigh the auto business against a robotics betThe Apex TimesBusinessAdobe shrugs off AI concerns as it posts record revenue, raises outlook and trades below 10 times expected earningsThe Apex TimesBusinessBroadcom CEO Calls AI Investors “Gamblers” as He Raises Guidance, Drawing Fresh ScrutinyThe Apex TimesBusinessAlphabet’s big EPS jump raises a familiar question: how much is real, and how much is accounting optics?The Apex TimesBusinessExxon Mobil shares trade at a premium as war-driven market swings collide with expectations for shrinking earningsThe Apex TimesBusinessCostco’s Shares Get a “Surprise” Label as Investors Look Back at the Past YearThe Apex TimesBusinessBank of America survey finds growing conviction that an AI “bubble” will emerge in 2027The Apex TimesBusinessUnitedHealth rises on strong Q3 results as investors weigh earnings and trim exposure to AI winnersThe Apex TimesBusinessNvidia Shares Dip as Broadcom and Microsoft News Filters Through the Chip SectorThe Apex TimesBusinessLeonardo DRS wins $63 million production order for Family of Weapon Sights, reinforcing dismounted sensing pushThe Apex TimesBusinessGoldman Sachs tops Street expectations in equity trading, while fixed income and rates lagThe Apex TimesBusinessPatient Capital Management points to Meta’s long-term upside in its 2026 investor letterThe Apex TimesBusinessTesla touts brisk vehicle deliveries, while investors weigh the auto business against a robotics betThe Apex TimesBusinessAdobe shrugs off AI concerns as it posts record revenue, raises outlook and trades below 10 times expected earningsThe Apex TimesBusinessBroadcom CEO Calls AI Investors “Gamblers” as He Raises Guidance, Drawing Fresh ScrutinyThe Apex TimesBusinessAlphabet’s big EPS jump raises a familiar question: how much is real, and how much is accounting optics?The Apex TimesBusinessExxon Mobil shares trade at a premium as war-driven market swings collide with expectations for shrinking earningsThe Apex TimesBusinessCostco’s Shares Get a “Surprise” Label as Investors Look Back at the Past YearThe Apex TimesBusinessBank of America survey finds growing conviction that an AI “bubble” will emerge in 2027The Apex TimesBusinessUnitedHealth rises on strong Q3 results as investors weigh earnings and trim exposure to AI winnersThe Apex TimesBusinessNvidia Shares Dip as Broadcom and Microsoft News Filters Through the Chip SectorThe Apex TimesBusinessLeonardo DRS wins $63 million production order for Family of Weapon Sights, reinforcing dismounted sensing pushThe Apex TimesBusinessGoldman Sachs tops Street expectations in equity trading, while fixed income and rates lagThe Apex TimesBusinessPatient Capital Management points to Meta’s long-term upside in its 2026 investor letterThe Apex TimesBusinessTesla touts brisk vehicle deliveries, while investors weigh the auto business against a robotics betThe Apex TimesBusinessAdobe shrugs off AI concerns as it posts record revenue, raises outlook and trades below 10 times expected earningsThe Apex TimesBusinessBroadcom CEO Calls AI Investors “Gamblers” as He Raises Guidance, Drawing Fresh ScrutinyThe Apex TimesBusinessAlphabet’s big EPS jump raises a familiar question: how much is real, and how much is accounting optics?The Apex TimesBusinessExxon Mobil shares trade at a premium as war-driven market swings collide with expectations for shrinking earningsThe Apex TimesBusinessCostco’s Shares Get a “Surprise” Label as Investors Look Back at the Past YearThe Apex TimesBusinessBank of America survey finds growing conviction that an AI “bubble” will emerge in 2027The Apex TimesBusinessUnitedHealth rises on strong Q3 results as investors weigh earnings and trim exposure to AI winnersThe Apex TimesBusinessNvidia Shares Dip as Broadcom and Microsoft News Filters Through the Chip SectorThe Apex TimesBusinessLeonardo DRS wins $63 million production order for Family of Weapon Sights, reinforcing dismounted sensing pushThe Apex TimesBusinessGoldman Sachs tops Street expectations in equity trading, while fixed income and rates lagThe Apex TimesBusinessPatient Capital Management points to Meta’s long-term upside in its 2026 investor letterThe Apex TimesBusinessTesla touts brisk vehicle deliveries, while investors weigh the auto business against a robotics betThe Apex TimesBusinessAdobe shrugs off AI concerns as it posts record revenue, raises outlook and trades below 10 times expected earningsThe Apex TimesBusinessBroadcom CEO Calls AI Investors “Gamblers” as He Raises Guidance, Drawing Fresh ScrutinyThe Apex TimesBusinessAlphabet’s big EPS jump raises a familiar question: how much is real, and how much is accounting optics?The Apex TimesBusinessExxon Mobil shares trade at a premium as war-driven market swings collide with expectations for shrinking earningsThe Apex TimesBusinessCostco’s Shares Get a “Surprise” Label as Investors Look Back at the Past YearThe Apex TimesBusinessBank of America survey finds growing conviction that an AI “bubble” will emerge in 2027The Apex TimesBusinessUnitedHealth rises on strong Q3 results as investors weigh earnings and trim exposure to AI winnersThe Apex TimesBusinessNvidia Shares Dip as Broadcom and Microsoft News Filters Through the Chip SectorThe Apex Times
Back to front
Prelude links KAT6A degrader PRT13722 with Eli Lilly’s breast cancer medicines in HR+/HER2- Phase 1 study
The Apex Times

THE APEX TIMES

Business/The Apex Times/Oct 13, 7:27 AM EDT

Prelude links KAT6A degrader PRT13722 with Eli Lilly’s breast cancer medicines in HR+/HER2- Phase 1 study

The collaboration pairs Prelude’s KAT6A selective degrader PRT13722 with Verzenio® and Inluriyo® across combination cohorts, with Prelude saying patient enrollment is expected to begin in the fourth quarter of 2026.

By The Apex Times Newsroom3 min readAI-assisted Apex article

Prelude Biosciences announced a clinical trial collaboration and supply agreement with Eli Lilly, aimed at evaluating Prelude’s KAT6A selective degrader PRT13722 in combination with two breast cancer medicines marketed by Lilly for patients with HR-positive, HER2-negative breast cancer.

In the planned Phase 1 study, Prelude said it is running combination cohorts that pair PRT13722 with Verzenio® and Inluriyo®. Verzenio is the brand name for Lilly’s CDK4/6 inhibitor abemaciclib, used in certain HR-positive, HER2-negative breast cancer settings. Inluriyo is a Lilly-branded oncology medicine, though the announcement does not provide clinical details about the specific regimen or lines of therapy being tested in combination with PRT13722 in the release.

KAT6A selective degraders are designed to reduce the activity of a cancer-associated protein by promoting its degradation inside cells, rather than simply blocking a target. Prelude’s PRT13722 is positioned in the company’s trial program as an add-on mechanism intended to deepen responses when combined with therapies that already target established breast cancer pathways.

Prelude said the combination-cohort program is on track to initiate enrollment in the fourth quarter of 2026. The statement frames this as part of an early-stage effort to assess combination activity and tolerability, which is typical for Phase 1 multi-drug studies that seek to define recommended dosing before expanding into larger, more definitive trials.

The collaboration also includes a supply agreement with Lilly. While the release indicates that Lilly will support supply for the study, it does not outline terms such as manufacturing responsibilities, quantities, or exclusivity provisions, leaving those specifics undisclosed in the materials made public through the market news post.

For Lilly, the deal reflects a common strategy in oncology drug development: partnering with developers of upstream or complementary mechanisms and using branded or established partner medicines within controlled clinical studies. For Prelude, it provides access to Lilly’s commercially available therapies for use alongside PRT13722, which can help accelerate the design and execution of combination cohorts in HR+/HER2- disease.

The announcement does not disclose additional endpoints, dose levels, trial site geography, or the number of patients expected to enroll in these combination cohorts. It also does not specify whether PRT13722 plus Verzenio and Inluriyo is being tested in a particular subpopulation, such as patients with prior treatment exposure, or what comparator arms, if any, are included in the trial design.

Investors and clinicians will likely focus next on how quickly Prelude enrolls once the fourth-quarter 2026 window arrives and on what Phase 1 data eventually show for combination tolerability and early indicates of anti-tumor activity. The company’s future disclosures, particularly any updated protocol details and interim safety readouts, would be key to understanding whether the mechanistic rationale translates into measurable clinical benefit.

Why It Matters

  • Combination oncology studies can accelerate drug development if early safety and activity support moving into later-stage trials.
  • The use of PRT13722 alongside established HR+/HER2- therapies suggests Prelude is testing whether a protein-degradation approach can enhance or extend responses from pathway-targeted treatments.
  • For Lilly, the agreement supports continued clinical engagement for its oncology portfolio and could inform future combination strategies in HR+/HER2- disease.
  • Timing is a near-term factor: if enrollment begins as planned in Q4 2026, the study could produce early data on a schedule that shapes subsequent development decisions.

Sources

Key Facts

  • Prelude and Eli Lilly entered a clinical trial collaboration and supply agreement related to PRT13722.
  • The Phase 1 program includes combination cohorts in HR-positive, HER2-negative breast cancer.
  • Prelude’s PRT13722 is described as a KAT6A selective degrader.
  • The combination regimens include PRT13722 with Lilly’s Verzenio® and Inluriyo®.
  • Prelude said enrollment for the program is on track to begin in the fourth quarter of 2026.
  • The announcement made public via market news does not provide dosing, patient numbers, or detailed endpoints.

Healthcare Related